In an effort to curb skyrocketing medical debt, the Hospital Price Transparency Rule mandates that U.S. hospitals disclose their "standard charges," yet this comprehensive analysis of over 1,300 facilities reveals a stark divide between technical compliance and actual transparency. While 93% of hospitals have adopted the required file formats, only 62% provide usable pricing data for high-expenditure medications, such as those used for cancer and multiple sclerosis treatment. This significant data gap — compounded by the discovery that prices for the same drug can fluctuate ten-fold or more depending on the specific payer contract — suggests that while the "information barriers" are beginning to crack, many hospitals are opting for "in-form" compliance rather than providing the genuine clarity needed to empower patients and foster a truly competitive market. This report provides an in-depth look at both the progress and lack of progress in arming consumers with the tools necessary to make informed decisions, as well as the stark differences and disconnect that hospital prices have from drug to drug, payer to payer, and hospital to hospital.
Read More